Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 69

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 69
---
 tumor growth in a murine xenograft model of aggressive human prostate cancer (PC3 cells) and decreased
cancer-cell viability in vitro in prostate, pancreatic, and triple-negative breast-cancer cell lines. In aging-related models, Telomir-1
reversed telomere shortening and restored telomere length beyond wild-type levels in an accelerated-aging zebrafish model mimicking Progeria
and Werner syndromes.

14

Additional
preclinical studies demonstrated disease-specific activity in degenerative and metabolic models. In an age-related macular-degeneration
(AMD) model, Telomir-1 restored visual function and retinal structure, reduced oxidative stress, and reconstituted multiple retinal layers,
supporting a potential regenerative mechanism in oxidative retinal injury. In a Wilson’s-disease model, Telomir-1 improved neuromotor
performance, reduced liver-copper accumulation, and normalized hepatic and renal histopathology scores, indicating multi-organ protective
effects distinct from traditional metal-chelating agents. In metabolic models of Type 2 diabetes, Telomir-1 improved glucose metabolism
and insulin sensitivity, consistent with its observed effects on mitochondrial and redox regulation.

Collectively,
these preclinical findings suggest that Telomir-1 may function as a multi-target small-molecule regulator that integrates metal-ion balance,
mitochondrial protection, epigenetic remodeling, and telomere preservation—biological processes thought to underlie aging, cancer,
metabolic dysfunction, and several related pathologies. Telomir-1 has not been evaluated in humans, and there is no assurance that these
preclinical results will translate into clinical safety or efficacy.

Recent
Developments — Binding Letter of Intent for Worldwide Rights to Telomir-1

On
October 17, 2025, we executed a binding Letter of Intent (the “LOI”) to acquire TELI Pharmaceuticals, Inc., thereby securing
worldwide rights to the Company’s lead investigational therapy, Telomir-1. The proposed transaction would align the Company’s
existing U.S. intellectual-property rights with TELI’s ex-U.S. portfolio, consolidating ownership across key territories including
Europe, Canada, Mexico, China, Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan, and the United Arab Emirates.

Under
the LOI, each outstanding share of TELI common stock would be exchanged for shares of the Company’s